teriparatide

Summary

Summary: A synthetic polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Top Publications

  1. ncbi Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
    Michael R McClung
    Oregon Osteoporosis Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Arch Intern Med 165:1762-8. 2005
  2. ncbi Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk
    Toshitaka Nakamura
    Department of Orthopedic Surgery, University of Occupational and Environmental Health, 1 1 Iseigaoka, Yahatanishi ku, Kitakyushu 807 8555, Japan
    J Clin Endocrinol Metab 97:3097-106. 2012
  3. ncbi Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use
    Anthony B Hodsman
    University of Western Ontario, St Joseph s Health Care, Room 2F 15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada
    Endocr Rev 26:688-703. 2005
  4. ncbi Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study
    Jan Borggrefe
    Medizinische Physik, Klinik für Diagnostische Radiologie, Universitatsklinikum Schleswig Holstein, Kiel, Germany
    J Bone Miner Res 25:472-81. 2010
  5. pmc Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)
    Bente L Langdahl
    Department of Endocrinology, Arhus University Hospital, Tage Hansens Gade 2, Arhus, 8000, Denmark
    Calcif Tissue Int 85:484-93. 2009
  6. ncbi Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    R M Neer
    Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 344:1434-41. 2001
  7. ncbi Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
    Per Aspenberg
    Orthopaedics, Linkoping University, Linkoping, Sweden
    J Bone Miner Res 25:404-14. 2010
  8. ncbi Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide
    S A Polyzos
    Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 13 Simou Lianidi, 551 34 Thessaloniki, Greece
    Osteoporos Int 23:1171-6. 2012
  9. ncbi Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
    Felicia Cosman
    Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    J Bone Miner Res 26:503-11. 2011
  10. ncbi Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    P D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO, USA
    Osteoporos Int 18:59-68. 2007

Detail Information

Publications256 found, 100 shown here

  1. ncbi Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
    Michael R McClung
    Oregon Osteoporosis Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Arch Intern Med 165:1762-8. 2005
    ..Recombinant teriparatide (human parathyroid hormone 1-34) stimulates bone formation, increases bone mass, and improves bone ..
  2. ncbi Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk
    Toshitaka Nakamura
    Department of Orthopedic Surgery, University of Occupational and Environmental Health, 1 1 Iseigaoka, Yahatanishi ku, Kitakyushu 807 8555, Japan
    J Clin Endocrinol Metab 97:3097-106. 2012
    Weekly teriparatide injection at a dose of 56.5 μg has been shown to increase bone mineral density.
  3. ncbi Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use
    Anthony B Hodsman
    University of Western Ontario, St Joseph s Health Care, Room 2F 15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada
    Endocr Rev 26:688-703. 2005
    ..PTH and its analog, teriparatide [recombinant human PTH(1-34)], represent a new class of anabolic therapies for the treatment of severe ..
  4. ncbi Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study
    Jan Borggrefe
    Medizinische Physik, Klinik für Diagnostische Radiologie, Universitatsklinikum Schleswig Holstein, Kiel, Germany
    J Bone Miner Res 25:472-81. 2010
    ..bone strength based on 3D quantitative computed tomography (QCT) of the femoral neck (FN) in subjects receiving teriparatide (TPTD). Fifty-two postmenopausal women with severe osteoporosis were analyzed...
  5. pmc Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)
    Bente L Langdahl
    Department of Endocrinology, Arhus University Hospital, Tage Hansens Gade 2, Arhus, 8000, Denmark
    Calcif Tissue Int 85:484-93. 2009
    The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries...
  6. ncbi Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    R M Neer
    Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 344:1434-41. 2001
    ..The 40-microg dose increased bone mineral density more than the 20-microg dose but had similar effects on the risk of fracture and was more likely to have side effects...
  7. ncbi Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
    Per Aspenberg
    Orthopaedics, Linkoping University, Linkoping, Sweden
    J Bone Miner Res 25:404-14. 2010
    Animal experiments show a dramatic improvement in skeletal repair by teriparatide. We tested the hypothesis that recombinant teriparatide, at the 20 microg dose normally used for osteoporosis treatment or higher, would accelerate fracture ..
  8. ncbi Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide
    S A Polyzos
    Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 13 Simou Lianidi, 551 34 Thessaloniki, Greece
    Osteoporos Int 23:1171-6. 2012
    ..Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment.
  9. ncbi Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
    Felicia Cosman
    Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    J Bone Miner Res 26:503-11. 2011
    ..with an intravenous infusion of zoledronic acid 5 mg and daily subcutaneous recombinant human (rh)PTH(1-34) (teriparatide) 20 µg versus either agent alone on bone mineral density (BMD) and bone turnover markers, we conducted a 1-..
  10. ncbi Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    P D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO, USA
    Osteoporos Int 18:59-68. 2007
    ..The prevalence of both osteoporosis and renal impairment increases with age...
  11. ncbi Of mice and men: divergent risks of teriparatide-induced osteosarcoma
    V Subbiah
    Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Osteoporos Int 21:1041-5. 2010
    Since approval by the U.S. Food and Drug Administration (FDA) in December 2002, teriparatide (recombinant 1-34 PTH; Forteo) has been safely used by more than 430,000 patients...
  12. ncbi Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    J Clin Endocrinol Metab 93:3785-93. 2008
    Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives...
  13. pmc Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
    M Shiraki
    Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, 1610 1 Meisei, Misato, Azumino, Nagano, 399 8101, Japan
    Osteoporos Int 24:219-26. 2013
    This study investigated the effects of a single administration of teriparatide on bone turnover markers in postmenopausal women...
  14. ncbi Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis
    Robert R Recker
    Osteoporosis Research Center, Creighton University School of Medicine, Omaha, Nebraska 68131, USA
    J Bone Miner Res 24:1358-68. 2009
    We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis...
  15. pmc Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis
    Joel S Finkelstein
    Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 95:1838-45. 2010
    b>Teriparatide increases both bone formation and bone resorption.
  16. pmc Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
    Joy N Tsai
    Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA
    Lancet 382:50-6. 2013
    ..The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone.
  17. ncbi Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws
    Y D Kwon
    Department of Oral and Maxillofacial Surgery, Kyung Hee University School of Dentistry, Hoegi dong, Dongdaenum ku, Seoul, 130 701, Republic of Korea
    Osteoporos Int 23:2721-5. 2012
    To review the effect of teriparatide as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws (BRONJ), we describe a series of cases of teriparatide therapy for the treatment of BRONJ and serial changes of serum ..
  18. ncbi Evidence that anabolic effects of PTH on bone require IGF-I in growing mice
    N Miyakoshi
    Musculoskeletal Disease Center, J L Pettis VA Medical Center, Loma Linda, California 92357, USA
    Endocrinology 142:4349-56. 2001
    ..These data to our knowledge provide the first direct evidence that the anabolic effects of PTH on bone formation in vivo require IGF-I action in growing mice...
  19. ncbi Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
    Yebin Jiang
    Osteoporosis and Arthritis Research Group, Department of Radiology, University of California, San Francisco, California 94143 0628, USA
    J Bone Miner Res 18:1932-41. 2003
    Histomorphometry and microCT of 51 paired iliac crest biopsy specimens from women treated with teriparatide revealed significant increases in cancellous bone volume, cancellous bone connectivity density, cancellous bone plate-like ..
  20. ncbi A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study
    A W C Kung
    Dept of Medicine, University of Hong Kong, Queen Mary Hospital, China
    Curr Med Res Opin 22:929-37. 2006
    ..As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal ..
  21. ncbi Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate
    Harald Dobnig
    Department of Internal Medicine, Division of Endocrinology and Nuclear Medicine, Medical University of Graz, Graz, Austria
    J Bone Miner Res 24:1998-2006. 2009
    ..Our objective was to study the effects of teriparatide treatment on changes in microdamage accumulation at the iliac crest in previously treatment-naïve patients or ..
  22. ncbi Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study
    Christian Graeff
    Medical Physics, Department of Diagnostic Radiology, Michaelisstrasse 9, D 24105 Kiel, Germany
    J Bone Miner Res 24:1672-80. 2009
    ..Finite element (FE) analysis-based strength measures were used to monitor a teriparatide therapy and the associated effects on whole bone and local fracture risk...
  23. ncbi Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
    Sarah J Glover
    University of Sheffield, Sheffield, UK
    Bone 45:1053-8. 2009
    b>Teriparatide, a parathyroid hormone analogue, is a potent anabolic treatment for postmenopausal osteoporosis...
  24. ncbi Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
    Robert Lindsay
    Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    Arch Intern Med 164:2024-30. 2004
    b>Teriparatide (recombinant human parathyroid hormone [1-34]) reduces fracture risk in postmenopausal women with osteoporosis. We assessed the safety and incidence of new vertebral fractures after withdrawal of teriparatide.
  25. ncbi Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
    J M Kaufman
    Department of Endocrinology, Ghent University Hospital, 9K121E, De Pintelaan 185, Ghent, Belgium
    Osteoporos Int 16:510-6. 2005
    b>Teriparatide (rhPTH[1-34]), a bone-forming agent for the treatment of osteoporosis, increases bone mineral density in men and women, and reduces the risk of fractures in women with osteoporosis...
  26. ncbi Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent
    Felicia Cosman
    Helen Hayes Hospital, West Haverstraw, New York 10993, USA
    J Clin Endocrinol Metab 94:3772-80. 2009
    The aim of the study was to assess adding vs. switching to teriparatide 20 microg/d in patients on alendronate or raloxifene.
  27. ncbi Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial
    Kenneth G Saag
    University of Alabama at Birmingham
    Arthritis Rheum 60:3346-55. 2009
    To compare the bone anabolic drug teriparatide (20 microg/day) with the antiresorptive drug alendronate (10 mg/day) for treating glucocorticoid-induced osteoporosis (OP).
  28. pmc Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women
    Felicia Cosman
    Regional Bone Center, Helen Hayes Hospital, West Haverstraw, New York, New York 10993, USA
    J Clin Endocrinol Metab 95:151-8. 2010
    Treatment of osteoporosis with an anabolic agent, teriparatide [human PTH 1-34 (TPTD)], is effective in reducing incident fractures, but patient resistance to daily sc injections has limited its use...
  29. ncbi Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts
    Benito R Losada
    Hospital Universitario de Caracas, Ciudad Universitaria, Los Chaguaramos, Caracas, Venezuela
    J Clin Densitom 12:63-70. 2009
    Glucocorticoid use is a leading cause of secondary osteoporosis. This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis...
  30. ncbi Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: a report of 3 cases
    Paul T Rubery
    Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Spinal Disord Tech 23:151-5. 2010
    ..Case Report...
  31. ncbi A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution
    Gayathri Subramanian
    PGY1, General Practice Residency Program, New Jersey Dental School Umdnj, Newark, NJ 07101, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:744-53. 2011
    ..The objective of this study was to present a comprehensive model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw (BON)...
  32. ncbi Femoral strength in osteoporotic women treated with teriparatide or alendronate
    Tony M Keaveny
    Department of Mechanical Engineering, 6175 Etcheverry Hall MC 1740, University of California, Berkeley, CA 94720 1740, USA
    Bone 50:165-70. 2012
    To gain insight into the clinical effect of teriparatide and alendronate on the hip, we performed non-linear finite element analysis of quantitative computed tomography (QCT) scans from 48 women who had participated in a randomized, ..
  33. pmc Anabolic agents and bone quality
    Tarek Sibai
    Department of Orthopaedic Surgery, Boston University Medical Center, 720 Harrison Avenue, Suite 808, Boston, MA 02118, USA
    Clin Orthop Relat Res 469:2215-24. 2011
    ....
  34. ncbi Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis
    Tony M Keaveny
    University of California, Berkeley, CA 94720 1740, USA
    J Bone Miner Res 22:149-57. 2007
    FE modeling was used to estimate the biomechanical effects of teriparatide and alendronate on lumbar vertebrae. Both treatments enhanced predicted vertebral strength by increasing average density...
  35. ncbi Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review
    Virgínia Fernandes Moça Trevisani
    Brazilian Cochrane Center, Universidade Federal de Sao Paulo Escola Paulista de Medicina UNIFESP EPM, Sao Paulo, Brazil
    Sao Paulo Med J 126:279-84. 2008
    ..b>Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting ..
  36. pmc Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
    Claudia Gagnon
    Department of Medicine, The University of Melbourne, Western Hospital, Cnr Eleanor and Marion Streets, Footscray, VIC 3011, Australia
    Clin Interv Aging 3:635-45. 2008
    ..b>Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in men...
  37. ncbi Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial
    David W Dempster
    Regional Bone Center, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
    J Clin Endocrinol Metab 97:2799-808. 2012
    ..Recent studies on the mechanism of action (MOA) of bone-active drugs have rekindled interest in how to present and interpret dynamic histomorphometric parameters of bone remodeling...
  38. ncbi Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography
    Michelle L Frost
    Osteoporosis Research Unit, Division of Imaging Sciences, King s College London, Guy s Campus, London, UK
    J Bone Miner Res 26:1002-11. 2011
    b>Teriparatide increases skeletal mass, bone turnover markers, and bone strength, but local effects on bone tissue may vary between skeletal sites...
  39. ncbi Successful treatment of sternal fracture nonunion with teriparatide
    S Chintamaneni
    Rheumatology, Stony Brook University Medical Center, New York, USA
    Osteoporos Int 21:1059-63. 2010
    ..While majority of fractures heal uneventfully, some fail to heal even after many months resulting in nonunion...
  40. ncbi Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
    Monique Arlot
    Laboratoire d Histodynamique Osseuse and INSERM Unit 403, Faculty of Medicine R Laennec, Lyon, France
    J Bone Miner Res 20:1244-53. 2005
    ..double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry. Biopsies were obtained from 42 patients...
  41. pmc Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life
    Annalisa Panico
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II, Naples, Italy
    Med Sci Monit 17:CR442-448. 2011
    We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
  42. ncbi Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance
    S A Foster
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Osteoporos Int 22:551-7. 2011
    Adherence to, and persistence with, treatments for osteoporosis are low. Adherence with teriparatide decreases over time. Higher copayments in the commercial/Medicare population were associated with worse persistence...
  43. ncbi Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis
    Fredrik Borgstrom
    i3 Innovus, Stockholm, Sweden, and LIME MMC, Karolinska Institute, Stockholm, Sweden
    J Med Econ 13:381-92. 2010
    ..the cost effectiveness from a societal perspective of the recombinant human parathyroid hormones: PTH(1-34) (teriparatide) and PTH(1-84) for patients with osteoporosis with similar characteristics to patients treated in normal ..
  44. ncbi The impact of teriparatide adherence and persistence on fracture outcomes
    S Yu
    Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street Room 241, Chicago, IL 60612, USA
    Osteoporos Int 23:1103-13. 2012
    The study investigated the real-world relationship between teriparatide adherence and persistence and fracture outcomes in a US claims database...
  45. ncbi Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis
    Peiqi Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Bone Miner Res 22:1173-80. 2007
    Increases in BMD are correlated with improvements in 2D and 3D trabecular microarchitecture indices with teriparatide treatment...
  46. ncbi Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium
    Robert Lindsay
    Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    J Bone Miner Res 22:495-502. 2007
    ..Enhanced bone formation was associated with an increase in osteoblast apoptosis...
  47. ncbi A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    Jean Jacques Body
    Department of Medicine, Institut J Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    J Clin Endocrinol Metab 87:4528-35. 2002
    b>Teriparatide (rDNA origin) injection [recombinant human PTH (1-34)] stimulates bone formation, increases bone mineral density (BMD), and restores bone architecture and integrity...
  48. ncbi An 18-month open-label trial of teriparatide in patients with previous parathyroidectomy at continued risk for osteoporotic fractures: an exploratory study
    Barry S Horowitz
    Metabolic Research Institute, Inc, West Palm Beach, FL, USA
    Endocr Pract 17:377-83. 2011
    To determine whether teriparatide increases lumbar spine bone mineral density (BMD) in patients who have undergone parathyroidectomy for primary hyperparathyroidism (PHPT) and are at continued risk for fracture.
  49. ncbi Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis
    S Adami
    Riabilitazione Reumatologica, University of Verona, Valeggio s Mincio, Verona, Italy
    Osteoporos Int 19:87-94. 2008
    Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given...
  50. ncbi Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy
    Stephen J Gomberg
    West Oaks Orthopaedic Associates, Thousand Oaks, California 91361, USA
    J Clin Endocrinol Metab 96:1627-32. 2011
    ..Oral bisphosphonates comprise the most widely prescribed class of antiosteoporotic drugs. Recent reports, however, propose a link between prolonged bisphosphonate use and atypical, low-energy, subtrochanteric fractures...
  51. ncbi Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS
    George Lyritis
    University of Athens, Greece
    Curr Med Res Opin 26:1799-807. 2010
    To investigate changes in back pain in postmenopausal women with severe osteoporosis who received teriparatide for 24 months or switched at 12 months to raloxifene or no active treatment.
  52. pmc Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
    R L Jilka
    Division of Endocrinology and Metabolism, UAMS Center for Osteoporosis and Metabolic Bone Diseases, and Central Arkansas Veterans Health Care System, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    J Clin Invest 104:439-46. 1999
    ..Moreover, it suggests novel pharmacotherapeutic strategies for osteoporosis and, perhaps, other pathologic conditions in which tissue mass diminution has compromised functional integrity...
  53. ncbi Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases
    Akimitsu Miyauchi
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe 651 0086, Japan
    Bone 47:493-502. 2010
    This multicenter study assessed the safety and efficacy of teriparatide 20 microg/day in Japanese men and women with osteoporosis at high risk of fracture during a 12-month, randomized, double-blind, placebo-controlled treatment period ..
  54. ncbi Development of an algorithm for using PINP to monitor treatment of patients with teriparatide
    Richard Eastell
    University of Sheffield, Sheffield, UK
    Curr Med Res Opin 22:61-6. 2006
    b>Teriparatide effects are mediated via the preferential stimulation of osteoblastic activity over osteoclastic activity. Amino-terminal propeptide of type I procollagen (PINP) is an indicator of osteoblastic activity.
  55. ncbi Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
    H M Macdonald
    Department of Mechanical and Manufacturing Engineering, Schulich School of Engineering, University of Calgary, 2500 University Drive, N W, Calgary, AB, T2N 1N4, Canada
    Osteoporos Int 22:357-62. 2011
    ..changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis...
  56. ncbi Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
    Peiqi Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Bone Miner Res 21:1785-90. 2006
    Increases in lumbar spine BMD account for 30-41% of the vertebral fracture risk reduction with teriparatide treatment. The remaining fracture risk reduction is caused by improvements in non-BMD determinants of bone strength.
  57. ncbi Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status
    B L Langdahl
    Aarhus University Hospital, Aarhus Sygehus, Tage Hansens Gade 2, 8000 Aarhus, Denmark
    Osteoporos Int 20:2095-104. 2009
    The effects of teriparatide versus alendronate were compared by gender and menopausal status in patients with glucocorticoid-induced osteoporosis...
  58. ncbi Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
    Richard Prince
    Department of Endocrinology and Diabetes and University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
    J Bone Miner Res 20:1507-13. 2005
    A follow-up in 1262 women was conducted after the discontinuation of teriparatide. The hazard ratio for combined teriparatide group (20 and 40 microg) for the 50-month period after baseline was 0.57 (p = 0...
  59. ncbi Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate
    Alan L Burshell
    Ochsner Clinic Foundation, Endocrinology Department, 9S Lobby Tower, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Bone 46:935-9. 2010
    ..bone mineral density (BMD) at 18 months in patients with glucocorticoid-induced osteoporosis (GIO) treated with teriparatide (n=80; 20 mug/day) or alendronate (n=77; 10 mg/day)...
  60. ncbi Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting
    Gerald Rajzbaum
    Hopital St Joseph, Paris, France
    Curr Med Res Opin 24:377-84. 2008
    ..fracture incidence, degree of pain, health-related quality of life (HRQoL) and compliance in women prescribed teriparatide in a community setting...
  61. ncbi Teriparatide: a review of its use in osteoporosis
    Stephanie K A Blick
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:2709-37. 2008
    Recombinant teriparatide (Forteo; Forsteo) is an anabolic (bone forming) agent...
  62. ncbi Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
    R Lindsay
    Helen Hayes Hospital, West Havershaw, NY, USA
    Osteoporos Int 20:943-8. 2009
    The extent to which fracture protection and safety varies with increasing time on teriparatide [rhPTH(1-34)] therapy is a clinically relevant unanswered question...
  63. ncbi Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
    M C Nevitt
    University of California, San Francisco, San Francisco, CA, USA
    Osteoporos Int 17:1630-7. 2006
    b>Teriparatide [rhPTH (1-34)] reduces fracture risk, and in a published meta-analysis of clinical trials, teriparatide-treated patients had reduced incidence of back pain relative to placebo or to antiresorptive drugs...
  64. ncbi Persistence with teriparatide in patients with osteoporosis: the UK experience
    N K Arden
    MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
    Osteoporos Int 17:1626-9. 2006
    The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
  65. pmc Teriparatide improves early callus formation in distal radial fractures
    Per Aspenberg
    Division of Orthopaedics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Sweden
    Acta Orthop 81:234-6. 2010
    b>Teriparatide (parathyreoid hormone; PTH 1-34) increases skeletal mass in humans and improves fracture healing in animals...
  66. ncbi Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]
    Richard P Harper
    Oral and Maxillofacial Surgery, University of Texas Southwestern Medical Center, Waco, and Corsicana 75110, USA
    J Oral Maxillofac Surg 65:573-80. 2007
  67. ncbi Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body
    Yan Chevalier
    Institute of Lightweight Design and Structural Biomechanics, Vienna, Austria
    Bone 46:41-8. 2010
    Previous antiresorptive treatment may influence the anabolic response to teriparatide. The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the ..
  68. ncbi Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
    J J Stepan
    Institute of Rheumatology, Faculty of Medicine, Charles University, Na Slupi 4, CZ12850, Prague, Czech Republic
    Osteoporos Int 21:2027-36. 2010
    The level of increased bone formation after 24 months of treatment with teriparatide (rhPTH (1-34), TPTD) is similar in patients who were either treatment-naïve (TN) or had lower bone turnover initially due to previous alendronate (ALN) ..
  69. ncbi Teriparatide or alendronate in glucocorticoid-induced osteoporosis
    Kenneth G Saag
    University of Alabama at Birmingham, Birmingham 35294 3408, USA
    N Engl J Med 357:2028-39. 2007
    ..Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking...
  70. pmc Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)
    A Fahrleitner-Pammer
    Medical University, Graz, Austria
    Osteoporos Int 22:2709-19. 2011
    ..in postmenopausal women with severe osteoporosis, the incidence of fractures was decreased during 18 months of teriparatide treatment with no evidence of further change in the subsequent 18-month post-teriparatide period when most ..
  71. ncbi Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
    J R Zanchetta
    Instituto de Investigaciones Metabolicas y Facultad de Medicina, Universidad del Salvador, Buenos Aires, Argentina
    J Bone Miner Res 18:539-43. 2003
    Treatment with teriparatide (rDNA origin) injection [teriparatide, recombinant human parathyroid hormone (1-34) [rhPTH(1-34)]] reduces the risk of vertebral and nonvertebral fragility fractures and increases cancellous bone mineral ..
  72. ncbi Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity
    Masahiko Sato
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Bone Miner Res 19:623-9. 2004
    OVX monkeys treated for 18 months with 1 or 5 microg/kg/d teriparatide [PTH (1-34)] had significantly stronger proximal femora relative to ovariectomized controls...
  73. ncbi Teriparatide and osseous regeneration in the oral cavity
    Jill D Bashutski
    Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA
    N Engl J Med 363:2396-405. 2010
    Intermittent administration of teriparatide, a drug composed of the first 34 amino acids of parathyroid hormone, has anabolic effects on bone...
  74. ncbi The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston 02114, USA
    N Engl J Med 349:1216-26. 2003
    ..Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone mineral density...
  75. ncbi Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis
    Jean Pierre Devogelaer
    Universite Catholique de Louvain, B 1200, Brussels, Belgium
    J Rheumatol 37:141-8. 2010
    ..studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a ..
  76. ncbi Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials
    Mary L Bouxsein
    Eli Lilly and Company, Indianapolis, Indiana, USA
    J Bone Joint Surg Am 91:1329-38. 2009
    ..preexisting) vertebral fractures on the risk of new adjacent vertebral fractures and to determine whether teriparatide (rhPTH [recombinant human parathyroid hormone] [1-34]) or raloxifene treatment reduces the incidence of ..
  77. ncbi A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide
    Robert Lindsay
    Clinical Research Center, New York State Department of Health, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
    J Bone Miner Res 21:366-73. 2006
    ..We show that 1 month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation...
  78. ncbi Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study
    Efstathios Mitsopoulos
    Department of Nephrology, Papageorgiou General Hospital, Thessaloniki, Greece
    Am J Nephrol 36:238-44. 2012
    ..Insufficient evidenced-based information is available for the treatment of osteoporosis in hemodialysis (HD) patients...
  79. ncbi Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34))
    Atsushi Watanabe
    Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, Shizuoka, Japan
    J Toxicol Sci 37:617-29. 2012
    b>Teriparatide, a therapeutic agent for osteoporosis, has been reported to increase the incidences of bone neoplasms such as osteosarcoma when administered subcutaneously to Fischer 344 (F344) rats for a long term, but its non-carcinogenic ..
  80. ncbi Teriparatide increases the maturation of circulating osteoblast precursors
    P D'Amelio
    Department of Surgical and Medical Disciplines Gerontology Section, University of Torino Italy, Corso Bramante 88 90, 10126 Torino, Italy
    Osteoporos Int 23:1245-53. 2012
    This study shows that teriparatide promotes the circulating osteoblast (OB) precursor degree of maturation in patients affected by postmenopausal osteoporosis.
  81. ncbi Teriparatide and fracture healing in cortical bone
    Thomas P Knecht
    Endocr Pract 10:293. 2004
  82. ncbi Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma
    Henrique Pierotti Arantes
    Bone and Mineral Unit, Division of Endocrinology, Sao Paulo Federal University, Sao Paulo, SP, Brazil
    J Bone Miner Res 26:2823-6. 2011
    ..The objective of this study was to evaluate the efficacy of teriparatide in a young man with OPPG...
  83. pmc Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
    Claus C Glüer
    Sektion Biomedizinische Bildgebung, Klinik für Diagnostische Radiologie, Universitatsklinikum Schleswig Holstein, Kiel, Germany
    J Bone Miner Res 28:1355-68. 2013
    ..5 standard deviations. Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months...
  84. pmc Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study
    Adi Cohen
    Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:1971-81. 2013
    ..Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture...
  85. ncbi [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections]
    Akimitsu Miyauchi
    Miyauchi medical center, Japan
    Clin Calcium 22:387-98. 2012
    b>Teriparatide (recombinant human PTH1-34 daily subcutaneous injection) has been approved for osteoporosis at high risk of fracture in many countries including Japan...
  86. ncbi The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
    P Hadji
    Department of Endocrinology, Osteoporosis, and Reproductive Medicine, Philipps University of Marburg, Marburg, Germany
    Osteoporos Int 23:2141-50. 2012
    The effect of teriparatide and risedronate on back pain was tested, and there was no difference in the proportion of patients experiencing a reduction in back pain between groups after 6 or 18 months...
  87. ncbi Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide
    N N C Carvalho
    Division of Endocrinology, Agamenon Magalhães Hospital, University of Pernambuco Medical School, 52061 540 Recife, Brazil
    J Clin Endocrinol Metab 96:2675-80. 2011
    ..Data are derived mainly from observation studies because a post hoc analysis from a randomized clinical trial did not find any such association...
  88. pmc Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS)
    J Bernard Walsh
    St James s Hospital and Trinity College, Dublin, Ireland
    Calcif Tissue Int 90:373-83. 2012
    ..describe clinical fracture incidence, back pain, and health-related quality of life (HRQoL) during 18 months of teriparatide treatment and 18 months post-teriparatide in the subgroup of 589 postmenopausal women with osteoporosis aged ≥..
  89. ncbi Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis
    Kathryn M Ryder
    Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA
    J Bone Miner Metab 28:233-9. 2010
    ..and safety study, men and women with severe developmental disabilities and osteoporosis received 20 mcg teriparatide subcutaneously daily for 18-24 months...
  90. ncbi Changes in vitamin D metabolites during teriparatide treatment
    Felicia Cosman
    Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    Bone 50:1368-71. 2012
    ..of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with ..
  91. pmc Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study
    Leslie Hazel-Fernandez
    Competitive Health Analytics Inc, Humana Inc, 3501 SW 160 Ave, Miramar, FL 33029, USA
    BMC Musculoskelet Disord 14:4. 2013
    ..The objective of this study was to evaluate the healthcare utilization patterns of Medicare Part D beneficiaries newly initiating teriparatide, and to assess the association of medication adherence and persistence with bone fracture.
  92. pmc Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis
    Benjamin Z Leder
    Endocrine Unit, THR 1047, Massachusetts General Hospital, 50 Blossom Street, Boston, MA 02114, USA
    J Clin Endocrinol Metab 94:2915-21. 2009
    In postmenopausal women, bone mineral density (BMD) declines after teriparatide therapy is stopped. The pattern of BMD loss after teriparatide therapy is stopped in men is less clear.
  93. ncbi Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy
    Cherie Ying Chiang
    Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia
    Bone 52:360-5. 2013
    ..The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated ..
  94. ncbi Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide
    Domenico Maugeri
    Department of Aging, Urological and Neurological Sciences, University of Catania, Cannizzaro Hospital, Via Messina 829, I 95126 Catania, Italy
    Arch Gerontol Geriatr 49:35-8. 2009
    ..During the last almost 3 years a new drug has become available in Italy, called teriparatide (rh-PTH-1-34), produced in Escherichia coli using the recombinant-DNA technique...
  95. ncbi Adherence and persistence in patients with severe osteoporosis treated with teriparatide
    V Ziller
    Department of Endocrinology, Reproductive Medicine and Osteoporosis, Philipps University of Marburg, Marburg, Germany
    Curr Med Res Opin 26:675-81. 2010
    ..weekly alendronate were still on treatment after 12 months. Data on adherence to teriparatide (TPTD) treatment of severe postmenopausal osteoporosis are available from only few countries...
  96. ncbi Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates
    Isabel Oliveira de Sousa
    Hospital Agamenon Magalhães, Universidade de Pernambuco, Recife, PE, Brasil
    Arq Bras Endocrinol Metabol 54:244-9. 2010
    To evaluate the responses of serum beta-CTX and osteocalcin in patients who were undergoing treatment with teriparatide or strontium ranelate (SR).
  97. ncbi [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis]
    Mitsuru Saito
    Department of Orthopaedic Surgery, Jikei University School of Medicine, Tokyo, Japan
    Clin Calcium 22:343-55. 2012
    ..Daily or once-weekly self-administered subcutaneous injection of human PTH (1-34) (teriparatide) increased bone mineral density (BMD) compared to a placebo in post-menopausal osteoporotic patients...
  98. pmc The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years
    Elizabeth B Andrews
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    J Bone Miner Res 27:2429-37. 2012
    ..commitment to the United States (US) Food and Drug Administration to evaluate a potential association between teriparatide, rhPTH(1-34), a recombinant human parathyroid hormone analog (self-injectable medication to treat osteoporosis),..
  99. ncbi Persistence with biologic therapies in the Medicare coverage gap
    Leonardo Tamariz
    MedMining, a Geisinger Health System Business, Danville, PA 17822 4012, USA
    Am J Manag Care 17:753-9. 2011
    To describe persistence with teriparatide and other biologic therapies in Medicare Part D plans with and without a coverage gap.
  100. ncbi The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1
    Davide Gatti
    University of Verona, Rheumatology Unit, Valeggio Hospital, Via Ospedale, Valeggio 37067, Verona, Italy
    J Clin Endocrinol Metab 96:1555-9. 2011
    The effect of teriparatide (TPD) on bone turnover is initially exuberant but then diminishes...
  101. ncbi Osteoporosis, teriparatide, and dosing of calcium and vitamin D
    Angelo A Licata
    N Engl J Med 352:1930-1. 2005

Research Grants63

  1. A MECHANISTIC STUDY OF SKELETAL ACTIONS OF 1-34hPTH
    Robert Lindsay; Fiscal Year: 2009
    The introduction of 1-34rhPTH (teriparatide) as a treatment for osteoporosis has been a major advance. Currently, the use of 1-34rhPTH is limited to 2 years of daily subcutaneous injections...
  2. IGF-1, bone turnover and response to teriparatide in premenopausal women with IOP
    Adi Cohen; Fiscal Year: 2013
    ..Moreover, women with IOP, low bone formation and high serum IGF-1 levels did not respond to teriparatide (TPTD), an osteo-anabolic medication that increases bone mineral density (BMD) by stimulating bone formation ..
  3. Synthesis of bone-selective osteogenic oxysterols
    Frank Stappenbeck; Fiscal Year: 2013
    ..Presently, there is only one FDA approved bone anabolic agent, Forteo (teriparatide) that confers significant clinical benefits in osteoporosis, but its use is severely restricted due to safety ..
  4. Early effects of PTH on the proximal femur
    Felicia Cosman; Fiscal Year: 2013
    ..b>Teriparatide (TPTD), the aminoterminal fragment of parathyroid hormone, increases BMD and bone strength and reduces fracture ..
  5. Genetics of Osteoblast Differentiation
    Matthew Aaron Hibbs; Fiscal Year: 2012
    ..Currently, only a single osteoblast promoting drug is approved by the FDA (teriparatide), but this compound carries significant risks and is thus indicated for use for no more than two years...
  6. Structure of sclerostin protein complexes
    Rajiv Kumar; Fiscal Year: 2012
    ..The only anabolic agent available now is teriparatide that must be administered parenterally. Sclerostin is an osteocyte derived protein that inhibits bone formation...
  7. OSTEOGENIC REGULATION OF VASCULAR CALCIFICATION
    Dwight A Towler; Fiscal Year: 2012
    ..Previously, we examined the impact of inflammation, teriparatide (suppresses vascular Msx2), and osteopontin (OPN) on aortic structure, calcification, and compliance...
  8. The interaction of anabolic and antiresorptive agents in osteoporosis therapy
    Joy Tsai; Fiscal Year: 2013
    ..In contrast to disappointing results from combining bisphosphonates with teriparatide (hPTH1-34 or TPTD), the combination of denosumab (DMAB), a monoclonal antibody that binds to receptor activator ..
  9. Novel Mechanism of PTH Effects on Bone Metabolism
    Bin Wang; Fiscal Year: 2013
    ..Over 300,000 hip fractures are caused by osteoporosis annually. Recombinant parathyroid hormone (PTH) 1-34 (teriparatide) is currently the only FDA-approved anabolic agent for treatment of osteoporosis in the United States...
  10. Sclerostin and Gsalpha signaling in osteoblasts
    JOY Y WU; Fiscal Year: 2012
    ..With the recent approval of recombinant human parathyroid hormone (teriparatide, PTH[1-34]), an anabolic agent with potent stimulatory effects on bone formation is now available...
  11. The role of class II histone deacetylases in PTH signaling in osteocytes
    MARC NATHAN WEIN; Fiscal Year: 2013
    ..In addition, a daily recombinant form of PTH (1-34, teriparatide) is the only FDA-approved anabolic osteoporosis treatment...
  12. The Role of PTH in the Low Bone Mass of Anorexia Nervosa
    POUNEH KHADEJEH FAZELI; Fiscal Year: 2013
    ..Therefore an agent which stimulates bone formation would be an important potential treatment. Currently teriparatide (PTH) is the only anabolic agent approved by the FDA for the treatment of osteoporosis...
  13. Black Bear Parathyroid Hormone as an Anabolic Agent for Bone
    SETH WARNER DONAHUE; Fiscal Year: 2011
    ..osteoporosis treatments since only one anabolic therapy (truncated recombinant human parathyroid hormone 1-34, teriparatide/Forteo(R)) is commercially available...
  14. PTH Effects of Craniofacial Allografts
    Edward M Schwarz; Fiscal Year: 2013
    ..in treating several patients with facture non-unions non- surgically with recombinant parathyroid hormone (PTH, teriparatide), in whom it appears that fibrous tissue was induced to form a boney union...
  15. Treatment of Hypoparathyroidism with Parathyroid Hormone
    John P Bilezikian; Fiscal Year: 2012
    ..b>Teriparatide [recombinant hPTH(1-34)] is another potential therapy but it is less attractive since it is an amino-terminal ..
  16. Translating molecular signal pathways to orthopaedic trauma care
    REGIS J O'KEEFE; Fiscal Year: 2013
    ..Project 1, "Teriparatide as a Therapy for Osteoarthritis Following Meniscal Injury" uses in vivo and in vitro preclinical models and ..
  17. Cyclic Versus Daily Teriparatide on Bone Mass, Microstructure and Strength
    Robert Lindsay; Fiscal Year: 2013
    ..ongoing study and takes advantage of this unique population of TPTD-treated patients to compare the effects of teriparatide given cyclically (8 three month cycles) over 4 years with teriparatide given daily for 2 years on BMD of the ..
  18. Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
    ELIZABETH J SHANE; Fiscal Year: 2013
    ..This proposal seeks for a Phase 2 clinical trial to investigate the efficacy and safety of teriparatide, human recombinant PTH, for IOP in premenopausal women...
  19. Effect of Teriparatide [hPTH(1-34)] on Vascular & Valvular Calcification in Human
    Robert Rifkin; Fiscal Year: 2008
    ..b>Teriparatide [rhPTH (1-34)], an agonist of this receptor, is the most potent agent in clinical use for increasing bone ..
  20. Targeting Bone Remodeling For the Treatment of Osteoporosis
    John Bilezikian; Fiscal Year: 2008
    ..The purpose of this meeting is to bring together experts from these interdisciplinary fields so as to define the direction of the future. ..
  21. EFFECTS OF ANDROGENS, ESTROGENS, AND PTH ON BONE
    Joel Finkelstein; Fiscal Year: 2008
    ..Without continued K24 support, I will need to increase my clinical activities, reduce my research time, and forego training of new clinical investigators. ..
  22. X-Treme CT Equipment Grant
    Joel Finkelstein; Fiscal Year: 2007
    ..We propose to use XtremeCT in a wide range of studies of bone disease that span a multitude of disciplines and serve a wide range of investigators in Boston and throughout New England. [unreadable] [unreadable] [unreadable]..
  23. 6th International Symposium on Osteoporosis
    Robert Lindsay; Fiscal Year: 2005
    ..abstract_text> ..
  24. Bone-Sparing by Ca Salts With & Without Extra Phosphorus
    Robert Heaney; Fiscal Year: 2008
    ..support of anabolic therapy of osteoporosis, we propose a 1-year randomized trial, comparing, in two groups of teriparatide-treated postmenopausal osteoporotic women, calcium supplements with and without extra phosphorus (i.e...
  25. BONY EFFECTS OF TRANSIENT NONSKELETAL ILLNESS
    Robert Heaney; Fiscal Year: 2001
    ....
  26. BISPHOSPHONATE BONE QUALITY IN WOMEN WITH BREAST CANCER
    Susan Ott; Fiscal Year: 2009
    ..Results of the study will provide valuable information about skeletal effects of high-dose bisphosphonates in humans. ..
  27. Sun Valley Workshop on Skeletal Biology
    David Burr; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  28. MULTIAXIAL STRENGTH BEHAVIOR OF HUMAN TRABECULAR BONE
    Tony M Keaveny; Fiscal Year: 2010
    ..This project should provide substantial insight into the roles of trabecular bone strength and bone quality on osteoporotic fracture risk and treatment and other orthopedic applications. ..
  29. Somatomedin: Autologous Regulator of Bone Formation
    Ernesto Canalis; Fiscal Year: 2008
    ..These investigations should clarify the role of CHOP in bone cell differentiation and function. [unreadable] [unreadable]..
  30. G-PROTEIN COUPLED RECEPTOR KINASES IN OSTEOGENESIS
    Robert Spurney; Fiscal Year: 2004
    ..Understanding the biochemical mechanisms that regulate hone formation could lead to the development of novel strategies for treating a wide variety of bone disorders that cause osteoporosis. ..
  31. Eliciting Patient Treatment Preferences for Osteoporosis
    Liana Fraenkel; Fiscal Year: 2008
    ..abstract_text> ..
  32. Genetic Analysis of Bone Structure and Strength
    Charles Turner; Fiscal Year: 2008
    ..abstract_text> ..
  33. IN VIVO REGULATION OF IL6 AND IL6R GENE EXPRESSION
    CHARLES O BRIEN; Fiscal Year: 2002
    ..Finally, cis-acting regulatory elements in the IL-6 promoter that are the targets for estrogen and PTH actions in vivo will be identified. ..
  34. The Role of Osteocyte Survival in Bone Strength
    Robert Weinstein; Fiscal Year: 2005
    ..The proposed research plan will reveal the role of osteocyte survival in bone strength and how osteocytes achieve this objective. ..
  35. TWO X-LINKED GENES THAT REGULATE MINERAL HOMEOSTASIS
    Michael Whyte; Fiscal Year: 2002
    ....
  36. Mentored Patient-Oriented Research Career Development Aw
    Kathryn Ryder; Fiscal Year: 2005
    ..This will be a double-blinded placebo-controlled trial of Mg (500 mg/day) in 92 healthy men and women between the ages of 55-75. ..
  37. THE PHOTOBIOLOGY OF VITAMIN D
    Michael Holick; Fiscal Year: 2005
    ..Results from this study should provide important new insights into the photoproduction of toxisterols and suprasterols in human skin and provide new information about their potential biologic functions in the skin. ..
  38. Flavocoxid: A Medical Food Therapy for Osteoarthritis
    Sarah Morgan; Fiscal Year: 2004
    ..This innovative compound has commercial potential with its expected efficacy comparable to or exceeding the currently marketed COX inhibitors but with fewer side effects and at a significantly lower cost. ..
  39. Assessement of Trabecular Bone Strength & Damage
    TONY KEAVENY; Fiscal Year: 2004
    ..abstract_text> ..
  40. Physiological regulation of FGF-23 by dietary phosphate
    SHERRI ANN BURNETT; Fiscal Year: 2004
    ..We anticipate that male and female participants will show different physiology. Finally, we anticipate that there will be a diurnal variation in FGF-23 that mirrors the diurnal variation in phosphate. ..
  41. Microcomputed Tomography Device (Scanco UCT40)
    Mary Bouxsein; Fiscal Year: 2004
    ..abstract_text> ..
  42. BASIC FIBROBLAST GROWTH FACTOR EXPRESSION IN BONE CELLS
    Marja Hurley; Fiscal Year: 2003
    ..abstract_text> ..
  43. MECHANOTRANSDUCTION IN BONE
    David Burr; Fiscal Year: 2003
    ..Data generated by this Program are intended to define some mechanisms by which fluid forces can regulate gene expression, and will attempt to validate these mechanisms by in vivo studies. ..
  44. NIH OSTEOPOROSIS & RELATED BONE DISEASES RESOURCE CENTER
    Bess Dawson Hughes; Fiscal Year: 2002
    ..Specific efforts include supporting the National Osteoporosis Data Group, collecting and disseminating definitive statistics on bone diseases and on conditions co-morbid with osteoporosis, and preparing summary reports. ..
  45. Sun Valley Workshop on Skeletal Biology
    David Burr; Fiscal Year: 2005
    ..An Advisory Panel is formed of session chairs. There are plans to advertise and distribute a summary of the workshop, partly using Web-based resources. ..
  46. MUSCULOSKELETAL TRAINING GRANT
    David Burr; Fiscal Year: 2006
    ..Two presentations were nominated for Young Investigator Awards by the ASBMR and the ORS. ..
  47. PTH (7-34) for Chemotherapy alopecia in Breast Cancer
    Michael Holick; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  48. REGULATION OF PTH ACTIVITY IN BONE BY BETA-ARRESTIN
    Mary Bouxsein; Fiscal Year: 2008
    ..Information gained from the proposed studies will be instrumental for developing new PTH1R ligands with improved signaling and biologic activity profiles for treatment of osteoporosis and other metabolic bone disorders. ..
  49. Regulation of Podocyte Function By Angiotensin II
    Robert Spurney; Fiscal Year: 2008
    ..abstract_text> ..
  50. Sun Valley Workshop on Skeletal Biology
    David Burr; Fiscal Year: 2007
    ..There are plans to advertise and distribute a summary of the workshop, partly using Web-based resources. [unreadable] [unreadable] [unreadable] [unreadable]..
  51. REGULATION OF PTH-INDUCED BONE ANABOLISM BY INFLAMMATORY LIPIDS
    Yin Tintut; Fiscal Year: 2007
    ..The proposed studies will determine how high cholesterol reduces efficacy of parathyroid hormone so that corrective strategies can be developed. [unreadable] [unreadable] [unreadable]..
  52. Biomechanics of Spine Fracture
    TONY KEAVENY; Fiscal Year: 2007
    ..abstract_text> ..
  53. Sun Valley Workshop on Skeletal Biology
    David Burr; Fiscal Year: 2006
    ..There are plans to advertise and distribute a summary of the workshop, partly using Web-based resources. [unreadable] [unreadable] [unreadable] [unreadable]..
  54. Cytoskeletal Modulation of Bone Cell Mechanosensitivity
    ALEXANDER ROBLING; Fiscal Year: 2006
    ..Insights into the mechanisms of mechanosensory loss and recovery hold potential in the public health arena for optimizing the positive effects of loading on bone mass, fragility, and fracture risk. ..
  55. Family Studies of Idiopathic Osteoporosis in Men
    Etah Kurland; Fiscal Year: 2006
    ....
  56. The University of Connecticut BRIDGES Network
    Marja Hurley; Fiscal Year: 2006
    ..An evaluation format has been designed to monitor the success of the program. Computerized records of student status and progress will be logged into NIH ESTAR and used for tracking outcomes. ..
  57. Aromatase inhibition in elderly hypogonadal men
    Benjamin Leder; Fiscal Year: 2009
    ..With these assessments, we will better define the relative roles of estrogens and androgens in the physiology of aging and explore the mechanisms underlying gonadal steroid action in older men. ..
  58. STRUCTURAL CONSEQUENCES OF POST-YIELD BEHAVIOR OF BONE
    TONY KEAVENY; Fiscal Year: 2003
    ..It is suggested that results should lead, therefore, to improved understanding of vertebral fracture etiology, and may motivate development of new drug treatments. ..
  59. EFFECT OF POTASSIUM BICARBONATE ON BONE AND MUSCLE
    Bess Dawson Hughes; Fiscal Year: 2008
    ....
  60. Sun Valley Workshop on Skeletal Biology
    David Burr; Fiscal Year: 2004
    ..An Advisory Panel is formed of session chairs. There are plans to advertise and distribute a summary of the workshop, partly using Web-based resources. ..
  61. Tooth Eruption: Role of Dental Follicle & PTH Receptor
    Laurie McCauley; Fiscal Year: 2006
    ..Furthermore, these studies will enhance our basic knowledge as to the role of PTHrP and PTH-1R interactions in controlling mineralized tissue homeostasis. ..
  62. DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONE
    Benjamin Leder; Fiscal Year: 2005
    ..These combined research and didactic endeavors will prepare the candidate to achieve his long-term goal to develop an independent research program focusing on the role of gonadal steroids in bone metabolism. ..